Comparing 5G Mobile Stroke Units to Standard Emergency Services for Stroke Treatment
Official title: Comparison of 5G Mobile Stroke Unit to Standard Management by Emergency Medical Services For Acute Ischemic Stroke Treatment：A Multicenter, Prospective, Open-label, Blinded Endpoint , Week-wise Randomized, Controlled Trial
Run by Beijing Emergency Medical Center · NCT06943885 · Data updated 2026-11-12
This study is testing whether using 5G Mobile Stroke Units can help stroke patients get better treatment compared to regular emergency services.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 952 (estimated) |
| Sponsor | Beijing Emergency Medical Center Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | April 25, 2025 |
| Main results expected | October 2028 |
| Study ends | July 2029 |
| Registry record updated | May 14, 2025 |
| Trial ID | NCT06943885 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older who exhibit symptoms consistent with acute ischemic stroke and can be treated within 4.5 hours of symptom onset.
✕Probably not a fit
Patients with severe primary diseases that limit life expectancy to less than one year or those participating in other interventional trials may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates the effectiveness of 5G Mobile Stroke Units (MSUs) compared to standard Emergency Medical Services (EMS) in treating acute ischemic stroke patients. It is a multicenter, prospective, open-label, blinded endpoint, week-wise randomized, controlled trial that allocates patients to receive either pre-hospital diagnosis and treatment in a 5G MSU or standard EMS management. The primary outcome is the distribution of modified Rankin Scale scores at three months post-treatment, assessing functional outcomes for patients treated within 4.5 hours of symptom onset. The study aims to determine if the 5G MSU approach can improve patient outcomes and safety in urban and rural areas of China.
Why it matters
Potential benefit: If successful, this study could lead to improved functional outcomes for stroke patients through faster and more effective treatment.
How similar studies have gone: While the concept of Mobile Stroke Units is relatively new, there is limited evidence regarding their advantages over standard EMS, making this study a critical evaluation of a novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. History and physical/neurological examination consistent with acute stroke. 2. Age≥18. 3. Last seen normal within 4hr 30 min of symptom onset. 4. Pre-stroke modified Rankin scale ≤3（Being able to ambulate）. 5. No rt-PA/TNK exclusions per guidelines, prior to CT scan or baseline labs. 6. Informed consent obtained from patient (if competent) or legal representative. Exclusion Criteria: 1. Malignant or other severe primary disease with life expectancy \<1 year. 2. Participation in other interventional randomized clinical trials within 3 months before enrollment.
Where it's running
-
Beijing Emergency Medical Center
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Principal investigator: Dou Li, MD — Beijing Emergency Medical Center
- Study coordinator: Jie Zhou, MD
- Email: zhoujie_zj94@163.com
- Phone: +86 13141020699
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Short-Term outside-in nerve stimulation for acute ischemic stroke
This trial tests whether a 5-day external trigeminal nerve stimulation given after stroke can help more patients recover better than a sham treatment.
-
Sevoflurane vs. Propofol for anesthesia in stroke patients undergoing clot-removal
This study tests whether sevoflurane or propofol used for anesthesia during endovascular treatment of an acute ischemic stroke affects the final brain damage and recovery.
-
Safety of adding NRICM301 to standard care for adults with acute ischemic stroke
This study tests whether adding NRICM301, a traditional Chinese medicine formula, to usual care is safe for adults with acute ischemic stroke.
-
Intracranial Recanalization with LT3001 in Acute Ischemic Stroke
This phase II study tests whether LT3001 given to adults with acute ischemic stroke can help reopen blocked brain arteries.
-
Mobilisation After Endovascular Stroke Treatment
This study checks whether moving around 12 hours after endovascular stroke treatment is as safe as moving around 24 hours for people with an acute ischemic stroke.
-
Endovascular therapy plus standard care vs standard care alone for distal and medium vessel strokes
In people with acute ischemic stroke due to distal or medium vessel blockages, this study tests whether adding endovascular treatment to the usual medical care helps improve outcomes compared with medical care alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.